KCNN4 and glioblastoma: In GBM, combining the KCa3.1 inhibitor TRAM-34 with temozolomide (TMZ) significantly decreases DNA synthesis and CSC survival compared to TMZ alone, also reducing tumour cell infiltration [101,102].